BERTHELSEN SPENCER R 4

4 · IONIS PHARMACEUTICALS INC · Filed Jul 19, 2023

Form 4

Period: 2023-07-17

Director

Transactions

Exercise/Conversion
Restricted Stock Unit
2023-07-17−5,333→ 4,677 total
Exercise: $0.00→ Common Stock (5,333 underlying)
Exercise/Conversion
Common Stock
2023-07-17+1,777→ 141,924 total
Exercise/Conversion
Restricted Stock Unit
2023-07-17−1,777→ 10,010 total
Exercise: $0.00→ Common Stock (1,777 underlying)
Exercise/Conversion
Common Stock
2023-07-17+5,333→ 147,257 total

Holdings

Footnotes (5)

[F1]Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
[F2]The reporting person disclaims beneficial ownership of all securities held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
[F3]Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
[F4]Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
[F5]Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

Documents

1 file